KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival

Science Translational Medicine

Volumn 5, Issue 169, 2013, Pages

  Hatami, Raheleh ^a   Sieuwerts, Anieta M ^b   Izadmehr, Sudeh ^a   Yao, Zhong ^a   Qiao, Rui Fang ^a   Papa, Luena ^a   Look, Maxime P ^b   Smid, Marcel ^b   Ohlssen, Jessica ^a   Levine, Alice C ^a   Germain, Doris ^a   Burstein, David ^a   Kirschenbaum, Alexander ^a   DiFeo, Analisa ^c   Foekens, John A ^b   Narla, Goutham ^a,d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KRUPPEL LIKE FACTOR 6; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KLF6 SV1 GENE; MAJOR CLINICAL STUDY; MASTECTOMY; MOUSE; NETHERLANDS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; SURVIVAL ANALYSIS; TWIST TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84872703162     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004688     Document Type: Article

References (93)

1. B. Weigelt, J. L. Peterse, L. J. van 't Veer, Breast cancer metastasis: Markers and models. Nat. Rev. Cancer 5, 591-602 (2005).
2. A. F. Chambers, A. C. Groom, I. C. MacDonald, Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2, 563-572 (2002).
3. A. Singh, J. Settleman, EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
4. B. Fisher, M. Bauer, D. L.Wickerham, C. K. Redmond, E. R. Fisher, A. B. Cruz, R. Foster, B. Gardner, H. Lerner, R. Margolese, R. Poisson, H. Shibata, H. Volk, Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52, 1551-1557 (1983).
5. P. Friedl, S. Alexander, Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 147, 992-1009 (2011).
6. K. Polyak, Heterogeneity in breast cancer. J. Clin. Invest. 121, 3786-3788 (2011).
7. K. Polyak, I. Haviv, I. G. Campbell, Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30-38 (2009).
8. J. A. Joyce, J. W. Pollard, Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9, 239-252 (2009).
9. M. J. Bissell, W. C. Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 17, 320-329 (2011).
10. C. L. Chaffer, R. A. Weinberg, A perspective on cancer cell metastasis. Science 331, 1559-1564 (2011).
11. G. Christofori, New signals from the invasive front. Nature 441, 444-450 (2006).
12. D. L. Gibbons, W. Lin, C. J. Creighton, Z. H. Rizvi, P. A. Gregory, G. J. Goodall, N. Thilaganathan, L. Du, Y. Zhang, A. Pertsemlidis, J. M. Kurie, Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23, 2140-2151 (2009).
13. G. P. Gupta, J. Massagué, Cancer metastasis: Building a framework. Cell 127, 679-695 (2006).
14. R. Kalluri, EMT: When epithelial cells decide to become mesenchymal-like cells. J. Clin. Invest. 119, 1417-1419 (2009).
15. D. X. Nguyen, P. D. Bos, J. Massagué, Metastasis: From dissemination to organ-specific colonization. Nat. Rev. Cancer 9, 274-284 (2009).
16. J. P. Thiery, Metastasis: Alone or together? Curr. Biol. 19, R1121-R1123 (2009).
17. J. P. Thiery, Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454 (2002).
18. J. P. Thiery, Cell adhesion in development: A complex signaling network. Curr. Opin. Genet. Dev. 13, 365-371 (2003).
19. J. P. Thiery, H. Acloque, R. Y. Huang, M. A. Nieto, Epithelial- mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
20. J. P. Thiery, J. P. Sleeman, Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142 (2006).
21. X. Wang, J. Zhao, KLF8 transcription factor participates in oncogenic transformation. Oncogene 26, 456-461 (2007).
22. X. Wang, M. Zheng, G. Liu, W. Xia, P. J. McKeown-Longo, M. C. Hung, J. Zhao, Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res. 67, 7184-7193 (2007).
23. J. Holian, W. Qi, D. J. Kelly, Y. Zhang, E. Mreich, C. A. Pollock, X. M. Chen, Role of Kruppel-like factor 6 in transforming growth factor-β1- induced epithelial-mesenchymal transition of proximal tubule cells. Am. J. Physiol. Renal Physiol. 295, F1388-F1396 (2008).
24. J. L. Yori, E. Johnson, G. Zhou, M. K. Jain, R. A. Keri, Kruppel-like factor 4 inhibits epithelial-to-mesenchymal transition through regulation of E-cadherin gene expression. J. Biol. Chem. 285, 16854-16863 (2010).
25. J. L. Yori, D. D. Seachrist, E. Johnson, K. L. Lozada, F. W. Abdul-Karim, L. A. Chodosh, W. P. Schiemann, R. A. Keri, Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 13, 601-610 (2011).
26. T. Shimamura, S. Imoto, Y. Shimada, Y. Hosono, A. Niida, M. Nagasaki, R. Yamaguchi, T. Takahashi, S. Miyano, A novel network profiling analysis reveals system changes in epithelial-mesenchymal transition. PLoS One 6, e20804 (2011).
27. K.Gumireddy, A. Li, P. A. Gimotty, A. J. Klein-Szanto, L. C. Showe, D. Katsaros, G. Coukos, L. Zhang, Q. Huang, KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat. Cell Biol. 11, 1297-1304 (2009).
28. G. Narla, A. DiFeo, S. Yao, A. Banno, E. Hod, H. L. Reeves, R. F. Qiao, O. Camacho-Vanegas, A. Levine, A. Kirschenbaum, A. M. Chan, S. L. Friedman, J. A. Martignetti, Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 65, 5761-5768 (2005).
29. A. DiFeo, G. Narla, J. Hirshfeld, O. Camacho-Vanegas, J. Narla, S. L. Rose, T. Kalir, S. Yao, A. Levine, M. J. Birrer, T. Bonome, S. L. Friedman, R. E. Buller, J. A. Martignetti, Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin. Cancer Res. 12, 3730-3739 (2006).
30. G. Narla, A. DiFeo, Y. Fernandez, S. Dhanasekaran, F. Huang, J. Sangodkar, E. Hod, D. Leake, S. L. Friedman, S. J. Hall, A. M. Chinnaiyan, W. L. Gerald, M. A. Rubin, J. A. Martignetti, KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118, 2711-2721 (2008).
31. G. Narla, A. Difeo, H. L. Reeves, D. J. Schaid, J. Hirshfeld, E. Hod, A. Katz, W. B. Isaacs, S. Hebbring, A. Komiya, S. K. McDonnell, K. E. Wiley, S. J. Jacobsen, S. D. Isaacs, P. C. Walsh, S. L. Zheng, B. L. Chang, D. M. Friedrichsen, J. L. Stanford, E. A. Ostrander, A. M. Chinnaiyan, M. A. Rubin, J. Xu, S. N. Thibodeau, S. L. Friedman, J. A. Martignetti, A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65, 1213-1222 (2005).
32. D. Vetter, M. Cohen-Naftaly, A. Villaneuva, Y. A. Lee, P. Kocabayoglu, R. Hannivoort, G. Narla, J. M. Llovet, S. N. Thung, S. L. Friedman, Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing. Hepatology 56, 1361-1370 (2012).
33. A. DiFeo, L. Feld, E. Rodriguez, C. Wang, D. G. Beer, J. A. Martignetti, G. Narla, A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Res. 68, 965-970 (2008).
34. M. Hartel, G. Narla, M. N. Wente, N. A. Giese, M. E. Martignoni, J. A. Martignetti, H. Friess, S. L. Friedman, Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer. Eur. J. Cancer 44, 1895-1903 (2008).
35. M. S. Teixeira, O. Camacho-Vanegas, Y. Fernandez, G. Narla, A. DiFeo, B. Lee, T. Kalir, S. L. Friedman, N. F. Schlecht, E. M. Genden, M. Urken, M. Brandwein-Gensler, J. A. Martignetti, KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int. J. Cancer 121, 1976-1983 (2007).
36. H. K. Chen, X. Q. Liu, J. Lin, T. Y. Chen, Q. S. Feng, Y. X. Zeng, Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas. Ai Zheng 21, 1047-1050 (2002).
37. H. L. Reeves, G. Narla, O. Ogunbiyi, A. I. Haq, A. Katz, S. Benzeno, E. Hod, N. Harpaz, S. Goldberg, S. Tal-Kremer, F. J. Eng,M. J. Arthur, J. A.Martignetti, S. L. Friedman, Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 126, 1090-1103 (2004).
38. S. Kremer-Tal, G. Narla, Y. Chen, E. Hod, A. DiFeo, S. Yea, J. S. Lee, M. Schwartz, S. N. Thung, I.M. Fiel, M. Banck, E. Zimran, S. S. Thorgeirsson, V. Mazzaferro, J. Bruix, J. A. Martignetti, J. M. Llovet, S. L. Friedman, Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J. Hepatol. 46, 645-654 (2007).
39. O. Camacho-Vanegas, G. Narla, M. S. Teixeira, A. DiFeo, A. Misra, G. Singh, A. M. Chan, S. L. Friedman, B. G. Feuerstein, J. A. Martignetti, Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int. J. Cancer 121, 1390-1395 (2007).
40. A. Tchirkov, V. Sapin, G. Marceau, E. Chautard, G. Narla, L. Veronese, S. Friedman, T. Khalil, P. Vago, J. L. Kemeny, P. Verrelle, Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin. Chem. Lab. Med. 48, 1167-1170 (2010).
41. A. DiFeo, J. A. Martignetti, G. Narla, The role of KLF6 and its splice variants in cancer therapy. Drug Resist. Updat. 12, 1-7 (2009).
42. T. Sørlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler,H. Johnsen, T. Hastie,M. B. Eisen,M. vande Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P.O. Brown, D. Botstein, P. E. Lønning, A. L. Børresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-10874 (2001).
43. J. Toussaint, A. M. Sieuwerts, B. Haibe-Kains, C. Desmedt, G. Rouas, A. L. Harris, D. Larsimont, M. Piccart, J. A. Foekens, V. Durbecq, C. Sotiriou, Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics 10, 424 (2009).
44. H. K. Kleinman, K. Jacob, Invasion assays. Curr. Protoc. Cell Biol. Chapter 12, Unit 12.2 (2001).
45. L. M. Shaw, Tumor cell invasion assays. Methods Mol. Biol. 294, 97-105 (2005).
46. A. Valster, N. L. Tran, M. Nakada, M. E. Berens, A. Y. Chan, M. Symons, Cell migration and invasion assays. Methods 37, 208-215 (2005).
47. A. A. van de Loosdrecht, G. J. Ossenkoppele, R. H. Beelen, M. G. Broekhoven, K.M. Schweitzer, M. M. Langenhuijsen, In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-g-activated monocytes. Cancer Immunol. Immunother. 38, 346-352 (1994).
48. A. Difeo, F. Huang, J. Sangodkar, E. A. Terzo, D. Leake, G. Narla, J. A. Martignetti, KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model. Cancer Res. 69, 4733-4741 (2009).
49. M. J. Bissell, D. Radisky, Putting tumours in context. Nat. Rev. Cancer 1, 46-54 (2001).
50. L. E. O'Brien, M. M. Zegers, K. E. Mostov, Opinion: Building epithelial architecture: insights from three-dimensional culture models. Nat. Rev. Mol. Cell Biol. 3, 531-537 (2002).
51. J. Debnath, S. K. Muthuswamy, J. S. Brugge, Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268 (2003).
52. J. Debnath, J. S. Brugge, Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 5, 675-688 (2005).
53. J. Debnath, K. R. Mills, N. L. Collins, M. J. Reginato, S. K. Muthuswamy, J. S. Brugge, The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111, 29-40 (2002).
54. H. Peinado, F. Portillo, A. Cano, Transcriptional regulation of cadherins during development and carcinogenesis. Int. J. Dev. Biol. 48, 365-375 (2004).
55. J. Sangodkar, A. DiFeo, L. Feld, R. Bromberg, R. Schwartz, F. Huang, E. A. Terzo, A. Choudhri, G. Narla, Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer 66, 292-297 (2009).
56. D. E. Jenkins, Y. S. Hornig, Y. Oei, J. Dusich, T. Purchio, Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res. 7, R444-R454 (2005).
57. A. J.Minn, G. P.Gupta, P. M. Siegel, P. D. Bos, W. Shu,D. D. Giri, A. Viale,A. B.Olshen, W. L. Gerald, J. Massagué, Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524 (2005).
58. Y. Kang, P. M. Siegel, W. Shu, M. Drobnjak, S. M. Kakonen, C. Cordón-Cardo, T. A. Guise, J. Massagué, A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537-549 (2003).
59. B. Thisse, M. el Messal, F. Perrin-Schmitt, The twist gene: Isolation of a Drosophila zygotic gene necessary for the establishment of dorsoventral pattern. Nucleic Acids Res. 15, 3439-3453 (1987).
60. S. Ansieau, J. Bastid, A. Doreau, A. P. Morel, B. P. Bouchet, C. Thomas, F. Fauvet, I. Puisieux, C. Doglioni, S. Piccinin, R. Maestro, T. Voeltzel, A. Selmi, S. Valsesia-Wittmann, C. Caron de Fromentel, A. Puisieux, Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14, 79-89 (2008).
61. J. Yang, S. A. Mani, J. L. Donaher, S. Ramaswamy, R. A. Itzykson, C. Come, P. Savagner, I. Gitelman, A. Richardson, R. A. Weinberg, Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
62. Y. Mironchik, P. T. Winnard Jr., F. Vesuna, Y. Kato, F. Wildes, A. P. Pathak, S. Kominsky, D. Artemov, Z. Bhujwalla, P. Van Diest, H. Burger, C. Glackin, V. Raman, Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res. 65, 10801-10809 (2005).
63. Y. Kang, J. Massagué, Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell 118, 277-279 (2004).
64. J. P. Thiery, Epithelial-mesenchymal transitions in cancer onset and progression. Bull. Acad. Natl. Med. 193, 1969-1978 (2009).
65. M. A. Eckert, T. M. Lwin, A. T. Chang, J. Kim, E. Danis, L. Ohno-Machado, J. Yang, Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 19, 372-386 (2011).
66. S. Ansieau, A. P. Morel, G. Hinkal, J. Bastid, A. Puisieux, TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 29, 3173-3184 (2010).
67. L. J. van 't Veer, H. Dai, M. J. van de Vijver, Y. D. He, A. A. Hart, M. Mao, H. L. Peterse, K. vander Kooy, M. J. Marton, A. T. Witteveen, G. J. Schreiber, R.M. Kerkhoven, C. Roberts, P. S. Linsley, R. Bernards, S. H. Friend, Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
68. M. J. van de Vijver, Y. D. He, L. J. van't Veer, H. Dai, A. A. Hart, D. W. Voskuil, G. J. Schreiber, J. L. Peterse, C. Roberts, M. J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E. T. Rutgers, S. H. Friend, R. Bernards, A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999-2009 (2002).
69. S. Ramaswamy, K. N. Ross, E. S. Lander, T. R. Golub, A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33, 49-54 (2003).
70. Y. Wang, J. G. Klijn, Y. Zhang, A. M. Sieuwerts, M. P. Look, F. Yang, D. Talantov, M. Timmermans, M. E. Meijer-van Gelder, J. Yu, T. Jatkoe, E. M. Berns, D. Atkins, J. A. Foekens, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
71. J. Yang, R. A. Weinberg, Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
72. D. S. Micalizzi, H. L. Ford, Epithelial-mesenchymal transition in development and cancer. Future Oncol. 5, 1129-1143 (2009).
73. H. Jeong, Y. J. Ryu, J. An, Y. Lee, A. Kim, Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. Histopathology 60, E87-E95 (2012).
74. S. Valastyan, R. A. Weinberg, Tumor metastasis: Molecular insights and evolving paradigms. Cell 147, 275-292 (2011).
75. M. A. Smit, T. R. Geiger, J. Y. Song, I. Gitelman, D. S. Peeper, A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol. Cell. Biol. 29, 3722-3737 (2009).
76. G. Xue, B. A. Hemmings, Phosphorylation of basic helix-loop-helix transcription factor Twist in development and disease. Biochem. Soc. Trans. 40, 90-93 (2012).
77. M. H. Yang, M. Z. Wu, S. H. Chiou, P. M. Chen, S. Y. Chang, C. J. Liu, S. C. Teng, K. J. Wu, Direct regulation of TWIST by HIF-1a promotes metastasis. Nat. Cell Biol. 10, 295-305 (2008).
78. S. Kremer-Tal, H. L. Reeves, G. Narla, S. N. Thung, M. Schwartz, A. Difeo, A. Katz, J. Bruix, P. Bioulac-Sage, J. A. Martignetti, S. L. Friedman, Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 40, 1047-1052 (2004).
79. J. Sangodkar, J. Shi, A. DiFeo, R. Schwartz, R. Bromberg, A. Choudhri, K. McClinch, R. Hatami, E. Scheer, S. Kremer-Tal, J. A. Martignetti, A. Hui, W. K. Leung, S. L. Friedman, G. Narla, Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur. J. Cancer 45, 666-676 (2009).
80. S. Yea, G. Narla, X. Zhao, R. Garg, S. Tal-Kremer, E. Hod, A. Villanueva, J. Loke, M. Tarocchi, K. Akita, S. Shirasawa, T. Sasazuki, J. A. Martignetti, J. M. Llovet, S. L. Friedman, Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134, 1521-1531 (2008).
81. S. Pece, D. Tosoni, S. Confalonieri, G. Mazzarol, M. Vecchi, S. Ronzoni, L. Bernard, G. Viale, P. G. Pelicci, P. P. Di Fiore, Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62-73 (2010).
82. H. Seol, H. J. Lee, Y. Choi, H. E. Lee, Y. J. Kim, J. H. Kim, E. Kang, S. W. Kim, S. Y. Park, Intratumoral heterogeneity of HER2 gene amplification in breast cancer: Its clinicopathological significance. Mod. Pathol. 25, 938-948 (2012).
83. S. Nik-Zainal, P. Van Loo, D. C. Wedge, L. B. Alexandrov, C. D. Greenman, K. W. Lau, K. Raine, D. Jones, J. Marshall, M. Ramakrishna, A. Shlien, S. L. Cooke, J. Hinton, A. Menzies, L. A. Stebbings, C. Leroy, M. Jia, R. Rance, L. J. Mudie, S. J. Gamble, P. J. Stephens, S. McLaren, P. S. Tarpey, E. Papaemmanuil, H. R. Davies, I. Varela, D. J. McBride, G. R. Bignell, K. Leung, A. P. Butler, J. W. Teague, S. Martin, G. Jönsson, O. Mariani, S. Boyault, P. Miron, A. Fatima, A. Langerød, S. A. Aparicio, A. Tutt, A. M. Sieuwerts, Å Borg, G. Thomas, A. V. Salomon, A. L. Richardson, A. L. Børresen-Dale, P. A. Futreal, M. R. Stratton, P. J. Campbell; Breast Cancer Working Group of the International Cancer Genome Consortium, The life history of 21 breast cancers. Cell 149, 994-1007 (2012).
84. C. Curtis, S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A. G. Lynch, S. Samarajiwa, Y. Yuan, S. Gräf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney; METABRIC Group, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L.Murphy, I. Ellis, A. Purushotham, A. L. Børresen-Dale, J. D. Brenton, S. Tavaré, C. Caldas, S. Aparicio, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
85. S. P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, A. Bashashati, L. M. Prentice, J. Khattra, A. Burleigh, D. Yap, V. Bernard, A. McPherson, K. Shumansky, A. Crisan, R. Giuliany, A. Heravi-Moussavi, J. Rosner, D. Lai, I. Birol, R. Varhol, A. Tam, N. Dhalla, T. Zeng, K. Ma, S. K. Chan, M. Griffith, A. Moradian, S. W. Cheng, G. B. Morin, P. Watson, K. Gelmon, S. Chia, S. F. Chin, C. Curtis, O. M. Rueda, P. D. Pharoah, S. Damaraju, J. Mackey, K. Hoon, T. Harkins, V. Tadigotla, M. Sigaroudinia, P. Gascard, T. Tlsty, J. F. Costello, I. M. Meyer, C. J. Eaves, W. W. Wasserman, S. Jones, D. Huntsman, M. Hirst, C. Caldas, M. A. Marra, S. Aparicio, The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
86. Y. Yuan, H. Failmezger, O. M. Rueda, H. R. Ali, S. Gräf, S. F. Chin, R. F. Schwarz, C. Curtis, M. J. Dunning, H. Bardwell, N. Johnson, S. Doyle, G. Turashvili, E. Provenzano, S. Aparicio, C. Caldas, F. Markowetz, Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med. 4, 157ra143 (2012).
87. H. Chen, L. Chen, L. Sun, H. Zhen, X. Li, Q. Zhang, A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer. Gastric Cancer 14, 339-352 (2011).
88. A. M. Sieuwerts, P. A. Usher, M. E. Meijer-van Gelder, M. Timmermans, J. W. Martens, N. Brünner, J. G. Klijn, H. Offenberg, J. A. Foekens, Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin. Chem. 53, 1280-1288 (2007).
89. J. A. Foekens, D. Atkins, Y. Zhang, F. C. Sweep, N. Harbeck, A. Paradiso, T. Cufer, A. M. Sieuwerts, D. Talantov, P. N. Span, V. C. Tjan-Heijnen, A. F. Zito, K. Specht, H. Hoefler, R. Golouh, F. Schittulli, M. Schmitt, L. V. Beex, J. G. Klijn, Y. Wang, Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
90. A. M. Sieuwerts, M. E. Meijer-van Gelder, M. Timmermans, A. M. Trapman, R. R. Garcia, M. Arnold, A. J. Goedheer, H. Portengen, J. G. Klijn, J. A. Foekens, How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: A retrospective study. Clin. Cancer Res. 11, 7311-7321 (2005).
91. T. van Agthoven, A. M. Sieuwerts, M. E. Meijer-van Gelder, M. P. Look, M. Smid, J. Veldscholte, S. Sleijfer, J. A. Foekens, L. C. Dorssers, Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J. Clin. Oncol. 27, 542-549 (2009).
92. M. Smid, Y. Wang, J. G. Klijn, A. M. Sieuwerts, Y. Zhang, D. Atkins, J. W. Martens, J. A. Foekens, Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24, 2261-2267 (2006).
93. M. Smid, Y. Wang, Y. Zhang, A. M. Sieuwerts, J. Yu, J. G. Klijn, J. A. Foekens, J. W. Martens, Subtypes of breast cancer show preferential site of relapse. Cancer Res. 68, 3108-3114 (2008).